A Swedish cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease
(2025) In Journal of Medical Economics 28(1). p.567-575- Abstract
Objectives: Iron deficiency anemia (IDA) is a common extraintestinal manifestation of inflammatory bowel disease (IBD), driven by impaired iron absorption, inflammation of intestinal mucosa and blood loss due to intestinal bleeding. Exogenous iron is indicated to correct iron deficiency, with intravenous iron preferred in patients with malabsorption or intolerance of oral iron, active bleeding, systemic inflammation, or a need for rapid iron replenishment. The objective was to assess the cost-utility of two high-dose, rapid-infusion iron formulations—ferric derisomaltose (FDI) and ferric carboxymaltose (FCM)—in the treatment of patients with IBD and IDA in Sweden. Methods: The analysis used a previously-published micro-simulation model.... (More)
Objectives: Iron deficiency anemia (IDA) is a common extraintestinal manifestation of inflammatory bowel disease (IBD), driven by impaired iron absorption, inflammation of intestinal mucosa and blood loss due to intestinal bleeding. Exogenous iron is indicated to correct iron deficiency, with intravenous iron preferred in patients with malabsorption or intolerance of oral iron, active bleeding, systemic inflammation, or a need for rapid iron replenishment. The objective was to assess the cost-utility of two high-dose, rapid-infusion iron formulations—ferric derisomaltose (FDI) and ferric carboxymaltose (FCM)—in the treatment of patients with IBD and IDA in Sweden. Methods: The analysis used a previously-published micro-simulation model. Phosphate monitoring was modeled based on the product labelling, while iron need and disease-related quality of life (QoL) were modeled based on data from the PHOSPHARE-IBD randomized controlled trial. Cost-utility was evaluated from the national healthcare payer perspective over a five-year time horizon. Sensitivity and scenario analyses were performed. Results: For each iron treatment course, patients treated with FDI required 0.41 fewer infusions than those treated with FCM. The reduced number of infusions resulted in savings of SEK 9,876 over five years from iron administration costs alone (SEK 44,216 with FCM versus SEK 34,340 with FDI). Phosphate monitoring in patients treated with FCM cost SEK 2,776 over five years versus no monitoring costs with FDI. Total cost savings with FDI were SEK 14,962. FDI also resulted in a 0.076 quality-adjusted life year (QALY) improvement versus FCM driven primarily by the QoL improvements reported in PHOSPHARE-IBD, and FDI was therefore the dominant intervention. Limitations: The analysis did not capture costs or outcomes associated with hypophosphatemic osteomalacia or fractures. Conclusion: Relative to FCM, fewer infusions of FDI were required, there was no need for phosphate monitoring, and disease-related QoL was improved, while overall costs were reduced.
(Less)
- author
- Lindgren, Stefan C. LU ; Strid, Hans ; Hjortswang, Henrik ; Manxhuka, Bardh ; Nanu, Neesha and Pollock, Richard F.
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cost-utility, ferric carboxymaltose, ferric derisomaltose, inflammatory bowel disease, iron deficiency anemia
- in
- Journal of Medical Economics
- volume
- 28
- issue
- 1
- pages
- 9 pages
- publisher
- Informa Healthcare
- external identifiers
-
- scopus:105002689244
- pmid:40167340
- ISSN
- 1369-6998
- DOI
- 10.1080/13696998.2025.2487359
- language
- English
- LU publication?
- yes
- id
- 90f8b6b8-3cb5-4bee-bb1f-b68de317fddf
- date added to LUP
- 2025-09-01 12:08:34
- date last changed
- 2025-10-14 10:58:52
@article{90f8b6b8-3cb5-4bee-bb1f-b68de317fddf,
abstract = {{<p>Objectives: Iron deficiency anemia (IDA) is a common extraintestinal manifestation of inflammatory bowel disease (IBD), driven by impaired iron absorption, inflammation of intestinal mucosa and blood loss due to intestinal bleeding. Exogenous iron is indicated to correct iron deficiency, with intravenous iron preferred in patients with malabsorption or intolerance of oral iron, active bleeding, systemic inflammation, or a need for rapid iron replenishment. The objective was to assess the cost-utility of two high-dose, rapid-infusion iron formulations—ferric derisomaltose (FDI) and ferric carboxymaltose (FCM)—in the treatment of patients with IBD and IDA in Sweden. Methods: The analysis used a previously-published micro-simulation model. Phosphate monitoring was modeled based on the product labelling, while iron need and disease-related quality of life (QoL) were modeled based on data from the PHOSPHARE-IBD randomized controlled trial. Cost-utility was evaluated from the national healthcare payer perspective over a five-year time horizon. Sensitivity and scenario analyses were performed. Results: For each iron treatment course, patients treated with FDI required 0.41 fewer infusions than those treated with FCM. The reduced number of infusions resulted in savings of SEK 9,876 over five years from iron administration costs alone (SEK 44,216 with FCM versus SEK 34,340 with FDI). Phosphate monitoring in patients treated with FCM cost SEK 2,776 over five years versus no monitoring costs with FDI. Total cost savings with FDI were SEK 14,962. FDI also resulted in a 0.076 quality-adjusted life year (QALY) improvement versus FCM driven primarily by the QoL improvements reported in PHOSPHARE-IBD, and FDI was therefore the dominant intervention. Limitations: The analysis did not capture costs or outcomes associated with hypophosphatemic osteomalacia or fractures. Conclusion: Relative to FCM, fewer infusions of FDI were required, there was no need for phosphate monitoring, and disease-related QoL was improved, while overall costs were reduced.</p>}},
author = {{Lindgren, Stefan C. and Strid, Hans and Hjortswang, Henrik and Manxhuka, Bardh and Nanu, Neesha and Pollock, Richard F.}},
issn = {{1369-6998}},
keywords = {{Cost-utility; ferric carboxymaltose; ferric derisomaltose; inflammatory bowel disease; iron deficiency anemia}},
language = {{eng}},
number = {{1}},
pages = {{567--575}},
publisher = {{Informa Healthcare}},
series = {{Journal of Medical Economics}},
title = {{A Swedish cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease}},
url = {{http://dx.doi.org/10.1080/13696998.2025.2487359}},
doi = {{10.1080/13696998.2025.2487359}},
volume = {{28}},
year = {{2025}},
}